Drug Trial Radar · NCT07662122
A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
345
Actual
Start
Jun 30, 2026
Primary completion
Jun 26, 2027
Study completion Jul 10, 2027
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Jun 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults between 18 and 74 years of age and who have a body mass index (BMI) of 30 kg/m2 or more, or a BMI of 27 kg/m2 or more and at least 1 health problem related to their weight. People who have previously not managed to lose weight by changing their diet can participate. People with type 2 diabetes cannot take part in this study. The purpose of this study is to find out whether a medicine called BI 3034701 helps people living with obesity or overweight to lose weight. This study has 7 groups of participants. Groups 1 to 6 get different doses of BI 3034701; Group 7 gets placebo. Placebo looks like BI 3034701 but does not contain any medicine. Every participant has more than an 80% chance of getting BI 3034701. Participants receive 2 injections of BI 3034701 or placebo under their skin for 42 weeks. In addition to the study medicine, all participants receive counselling to make changes to their diet and to exercise regularly. Participants are in the study for about 10 months. During this time, they visit the study site 15 times. The study doctors regularly measure the participants' body weight and take necessary laboratory tests. Participants also answer questions about their well-being and note their food intake and physical activity in diaries. The results will be compared between groups of participants to see whether the treatment works. The study doctors also regularly check participants' health and take note of any unwanted effects.
Conditions
- Obesity
- Overweight
Interventions
BI 3034701Drug
BI 3034701
Placebo matching BI 3034701Drug
Placebo matching BI 3034701
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage change in body weight from baseline at Week 42 [%]Time frame: Baseline and at Week 42.
Locations
55 sites in 6 countries. Site status is shown where the registry gives one.
Cahaba Research, Inc. - Trussville Location
Birmingham, Alabama
Focus Clinical Research
West Hills, California
Optimus U Corporation-Miami-69452
Miami, Florida
Javara-Fayetteville-67354
Fayetteville, Georgia
Monroe Biomedical Research - Louisville
Louisville, Kentucky
Arcturus Healthcare - Troy Internal Medicine Research Division
Troy, Michigan
StudyMetrix Research, LLC
City of Saint Peters, Missouri
Clinvest Research LLC
Springfield, Missouri
Centricity Research - Morehead City
Morehead City, North Carolina
Accellacare-Wilmington-67123
Wilmington, North Carolina
Lillestol Research, LLC
Fargo, North Dakota
Tribe Clinical Research at Parkside OB-GYN, Greer
Greer, South Carolina
Texas Diabetes and Endocrinology - Central Austin
Austin, Texas
South Texas Research Institute - Brownsville
Brownsville, Texas
South Texas Research Institute - Edinburg
Edinburg, Texas
IMA Clinical Research San Antonio
San Antonio, Texas
Data Point Clinical, LLC
Kirkland, Washington
Rainier Clinical Research Center
Renton, Washington
Allegiance Research Specialists
Wauwatosa, Wisconsin
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
Coastal Digestive Health & CDH Research Institute
Maroochydore, Queensland, Australia
Southern Adelaide Diabetes and Endocrine Services (SADES)
Oaklands Park, South Australia, Australia
Eastern Health-Box Hill Hospital
Box Hill, Victoria, Australia
Diex Recherche (Quebec)
Québec, Canada
Ocean West Research Clinic (Surrey)
Surrey, British Columbia, Canada
Hilltop Medical Clinic
Surrey, British Columbia, Canada
Dr. M. B. Jones Inc.
Victoria, British Columbia, Canada
Apex Trials (Guelph)
Guelph, Ontario, Canada
Winterberry Research Inc.
Hamilton, Ontario, Canada
The Wharton Medical Clinic Clinical Trials Inc.
Hamilton, Ontario, Canada
Milestone Research Inc.
London, Ontario, Canada
Stouffville Medical Research Institute Inc.
Stouffville, Ontario, Canada
Canadian Phase Onward Inc.
Toronto, Ontario, Canada
Ecogene-21
Chicoutimi, Quebec, Canada
THEO Medical (Montreal)
Montreal, Quebec, Canada
Centre Medical Acadie (9109-0126 Quebec Inc)
Montreal, Quebec, Canada
Diex Recherche (Sherbrooke Est)
Sherbrooke, Quebec, Canada
Diex Recherche (Victoriaville)
Victoriaville, Quebec, Canada
Huzhou Central Hospital
Huzhou, China
Center Hospital of Jinan
Jinan, China
Showing 40 of 55 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.